Analysts have clear opinions on FOLD.

There are 4 analysts on the Wall offering 12 month price targets for Amicus in the last 3 months. The average price target is $22.75 with a high forecast of $31.00 and a low forecast of $20.00. The average price target represents a 107.19% increase from the last price of $10.98.
Amicus Therapeutics, Inc. (FOLD) is followed by 4 analysts on the street.

Eliana Merle from Cantor Fitzgerald rates it a Buy with a target of $20.00.

Similarly, Last month Ritu Baral of Cowen & Co. Reiterated a Buy with a target of $31.00.

The consensus on the street is null.

What does Amicus Therapeutics, Inc.(FOLD) do ?
Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

Amicus Therapeutics, Inc. (FOLD) Insider Trades

Looking for stocks just like FOLD?

Based on Wall Street analyst research, several stocks are similar to FOLD
They are:
– BMRN [Info can be found here: ]
– RARE [Info can be found here: ]
– ABEO [Info can be found here: ]